Son, Jinsook http://orcid.org/0000-0002-0836-2626
Du, Wen
Esposito, Mark http://orcid.org/0000-0002-5724-4087
Shariati, Kaavian
Ding, Hongxu http://orcid.org/0000-0002-7846-9744
Kang, Yibin http://orcid.org/0000-0002-1626-6730
Accili, Domenico http://orcid.org/0000-0002-6874-3949
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK64819, DK63608, F32DK117574)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Article History
Received: 25 July 2022
Accepted: 26 January 2023
First Online: 2 February 2023
Competing interests
: D.A. is the founder, director, and chairman of the SAB of Forkhead Biotherapeutics, corp. M.E. and Y.K. own equity in Kayothera Inc, which holds the license to KOTX1. The remaining authors declare no other competing interests.